- Exchange: NASDAQ GS
- Sector: Consumer, Non-cyclical
- Industry: Pharmaceuticals
- Sub-Industry: Medical-Drugs
Clovis Oncology Inc
+ Add to WatchlistCLVS:US
33.2900 USD 1.9000 5.40%As of 20:10:00 ET on 05/22/2013.
Snapshot for Clovis Oncology Inc (CLVS)
| Open: | 35.1400 | Day's Range: | 33.1300 - 35.3400 | Volume: | 237,355 |
|---|---|---|---|---|---|
| Previous Close: | 33.2900 | 52wk Range: | 11.1900 - 40.2700 | 1-Yr Rtn: | +76.42% |
Key Statistics for CLVS
| Current P/E Ratio (ttm) | - |
|---|---|
| Estimated P/E(12/2013) | - |
| Relative P/E vs. SPX | - |
| Earnings Per Share (USD) (ttm) | -2.7200 |
| Est. EPS (USD) (12/2013) | -2.7750 |
| Est. PEG Ratio | - |
| Market Cap (M USD) | 874.36 |
| Shares Outstanding (M) | 26.27 |
| 30 Day Average Volume | 189,633 |
| Price/Book (mrq) | 7.2895 |
| Price/Sale (ttm) | - |
| Dividend Indicated Gross Yield | -% |
| Cash Dividend | - |
| Last Dividend | |
| 5 Year Dividend Growth | - |
| Next Earnings Announcement | 08/08/2013 |
mrq = Most Recent Quarter; ttm = Trailing Twelve Months
Income Statement for CLVS
No data available
Company Profile & Key Executives for CLVS
Clovis Oncology Inc. is a biopharmaceutical company. The Company is focused on acquiring, developing and commercializing innovative anti-cancer agents in the United States, Europe and additional international markets. Clovis target its development programs for the treatment of specific subsets of cancer populations.
| Patrick J MahaffyPresident/CEO/Co-Founder | Erle T MastExec VP/CFO/Secy/Co-Founder |
| Gillian C Ivers-ReadExec VP/Chief Regulatory Ofcr | Andrew R AllenExec VP/Chief Medical Ofcr |
Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.
Sponsored Financial Commentaries
Advertisement
Top Forex Trading Resources
-
CLVS News
-
Industry News
Advertisement
Advertisement
Sponsored Links
Advertisements
Rate this Page